Physician profile
James Yu
NPI 1831686062
$4,179.95
in general payments reported to CMS, 2019-2025
12 companies · $144 in 2025
The $144 reported for 2025 was less than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $941 · 2023: $2,205 · 2024: $889 · 2025: $144.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,424 · Travel and Lodging: $815.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,423.93 |
| Travel and Lodging | $814.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $2,664.05 | 2022-2025 | Superion Indirect Decompression System, Wavewriter Alpha Prime 16, General - Pain Management |
| Abbott Laboratories | $327.03 | 2024 | Proclaim |
| Vertos Medical, INC. | $307.04 | 2023 | Mild Device Kit |
| Painteq LLC | $204.98 | 2023-2024 | Painteq |
| Medtronic, INC. | $151.68 | 2022-2024 | Intellis Adaptivestim, Synchromedii |
| Abbvie INC. | $149.59 | 2023-2025 | Botox |
| Saluda Medical Americas, INC. | $116.95 | 2024 | Evoke |
| Spr Therapeutics, INC | $106.15 | 2024-2025 | Sprint Pns System |
| Nevro Corp. | $85.46 | 2024 | Senza |
| Zimmer Biomet Holdings, INC. | $24.69 | 2024 | Gel-One Cross-Linked Hyaluronate |
| Depuy Synthes Sales INC. | $22.40 | 2024 | Orthovisc, Monovisc |
| Collegium Pharmaceutical, INC. | $19.93 | 2024 | Xtampza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Yu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.